Antitrust risk-shifting provisions in Merck & Co., Inc./Prometheus Biosciences, Inc. merger agreement | Practical Law

Antitrust risk-shifting provisions in Merck & Co., Inc./Prometheus Biosciences, Inc. merger agreement

Antitrust risk-shifting provisions in Merck & Co., Inc./Prometheus Biosciences, Inc. merger agreement

Antitrust risk-shifting provisions in Merck & Co., Inc./Prometheus Biosciences, Inc. merger agreement

April 15, 2023 • Antitrust Risk-shifting • $10.8 billion

End of Document

© 2024 Thomson Reuters. No claim to original U.S. Government Works.